drugset / Trial / NCT05449535
Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This phase Ia study is meant to evaluate the tolerability, safety, pharmacokinetics, preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904, an anti-immunoglobulin E (IgE) antibody, in healthy Chinese subjects.
Timeline
- Start
- 2022-05-07
- Primary completion
- 2023-01-10
- Completion
- 2023-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OZUREPRUBART | Monoclonal antibody | — | Subcutaneous |
| Comparator | Omalizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.